Impact of acute temperature and air pollution exposures on adult lung function: A panel study of asthmatics

Richard Evoy, Laurel Kincl, Diana Rohlman, Lisa M. Bramer, Holly M. Dixon, Perry Hystad, Harold Bae, Michael Barton, Lisa M. Miller, Katrina M. Waters, Julie B. Herbstman, Kim A. Anderson

1 College of Public Health and Human Sciences, Oregon State University, Corvallis, Oregon, United States of America
2 Superfund Research Program, Oregon State University, Corvallis, Oregon, United States of America
3 Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, United States of America
4 Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon, United States of America
5 Computing & Analytics Division, Pacific Northwest National Laboratory, Richland, Washington, United States of America
6 Icahn School of Medicine at Mount Sinai, New York City, New York, United States of America
7 Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York City, New York, United States of America

* evoyr@oregonstate.edu

Abstract

Background

Individuals with respiratory conditions, such as asthma, are particularly susceptible to adverse health effects associated with higher levels of ambient air pollution and temperature. This study evaluates whether hourly levels of fine particulate matter (PM$_{2.5}$) and dry bulb globe temperature (DBGT) are associated with the lung function of adult participants with asthma.

Methods and findings

Global positioning system (GPS) location, respiratory function (measured as forced expiratory volume at 1 second (FEV$_1$)), and self-reports of asthma medication usage and symptoms were collected as part of the Exposure, Location, and Lung Function (ELF) study. Hourly ambient PM$_{2.5}$ and DBGT exposures were estimated by integrating air quality and temperature public records with time-activity patterns using GPS coordinates for each participant ($n = 35$). The relationships between acute PM$_{2.5}$, DBGT, rescue bronchodilator use, and lung function collected in one week periods and over two seasons (summer/winter) were analyzed by multivariate regression, using different exposure time frames.

In separate models, increasing levels in PM$_{2.5}$, but not DBGT, were associated with rescue bronchodilator use. Conversely DBGT, but not PM$_{2.5}$, had a significant association with FEV$_1$. When DBGT and PM$_{2.5}$ exposures were placed in the same model, the strongest association between cumulative PM$_{2.5}$ exposures and the use of rescue bronchodilator was identified at the 0–24 hours (OR = 1.030; 95% CI = 1.012–1.049; p-value = 0.001) and 0–48 hours (OR = 1.030; 95% CI = 1.013–1.057; p-value = 0.001) prior to lung function measure.
Conversely, DBGT exposure at 0 hours ($\beta = 3.257; \text{SE} = 0.879; \text{p-value} > 0.001$) and 0–6 hours ($\beta = 2.885; \text{SE} = 0.903; \text{p-value} = 0.001$) hours before a reading were associated with FEV$_1$. No significant interactions between DBGT and PM$_{2.5}$ were observed for rescue bronchodilator use or FEV$_1$.

Conclusions

Short-term increases in PM$_{2.5}$ were associated with increased rescue bronchodilator use, while DBGT was associated with higher lung function (i.e. FEV$_1$). Further studies are needed to continue to elucidate the mechanisms of acute exposure to PM$_{2.5}$ and DBGT on lung function in asthmatics.

Introduction

Ambient air pollution has adverse health effects in susceptible populations, such as those with respiratory diseases [1,2]. Extremes in ambient temperatures may also induce symptoms or exacerbations in asthmatics [3–6]. As climate change continues to cause temperature extremes and create conditions that increase air pollution, it is important to examine the combined effect of increased temperature and air pollution on human health, especially in susceptible populations [2].

Exposure to air pollution, both naturally occurring (wildfires) and manmade (exhaust), is related to increased hospitalization rates, emergency room visits, asthma exacerbations, and reduced lung function in the United States (US) [7–10]. In 2013, asthma was a significant economic burden for Americans and totaled approximately $81.9 billion when both direct and indirect impacts were taken into account [11]. While air pollution has decreased in the US due to efforts to limit greenhouse emissions, regional climate change, and industrial emissions can increase air pollution. One region is the US Pacific Northwest, where an increase in daily maximum temperatures and wildfires are expected to result in higher air pollution levels during the summers [12].

Previous studies have looked at the impacts of air pollution and temperature on asthma exacerbation, bronchodilator use, and lung function [5,6,13–26] independently, but there is a need to explore their interactive relationship relative to respiratory health in individuals with asthma. For studies that examine air pollution and lung function, only the temperature at the exact time of a lung function reading is usually recorded. Only one study we have identified examines temperature, air pollution, and lung function but was focused on healthy adults [22]. Asthmatics are considered to be susceptible to higher levels of air pollution and studies have shown that increased exposure to ambient and personal PM$_{2.5}$ levels can decrease lung function and increase rescue bronchodilator use [15,17–19,22,23,25–30]. Temperature is positively correlated with lung function when personal air pollutant exposure is limited or controlled in asthmatics [3–5,31]. However, studies have also shown the extreme cold or heat can also cause decreases in lung function. [5,6,21,32]. Forced expiratory volume at 1 second (FEV$_1$) is a common lung function measurement used to assess obstructive lung physiology and rescue bronchodilator use can act as a surrogate for subjective asthma symptoms. The relationships between air pollution, temperature, and lung function can be further elucidated using spatiotemporal methods coupled with participant global positioning system (GPS) tracking and stationary monitoring of environmental conditions.
During the summer of 2017, the Willamette Valley in Oregon experienced some of the worst air pollution in the US due to smoke from wildfires in Oregon and California [33]. During this time, the Exposure, Location, and Lung Function (ELF) tool was being deployed to participants in Eugene, OR which is located in the Willamette Valley. The ELF tool is an environmental health assessment tool that collects personal data including chemical exposures (passive wristband sampler), location (mobile phone GPS) and lung function measures (spirometry) as well as self-reported information (through the ELF Tracker application at the time of measures) [34]. The ELF tool relies on community-engaged research which represents a novel way to quickly gather data with participants collecting their own data. While some loss of potential accuracy may be present, researchers do gain a broader representation of participation. In addition, as recent public health emergencies, like the COVID-19 pandemic has shown, there are times when research can be conducted in collaboration with communities when researchers do not have access to the communities or medical facilities. In this panel analysis, we examine how exposure metrics from public data for PM$_{2.5}$ and temperature are associated with the lung function (i.e. FEV$_1$) of participants and rescue bronchodilator use.

**Materials and methods**

**Study design**

This panel study used data from 35 physician-diagnosed asthmatics who enrolled in the ELF study from 2017 to 2018. Participants were recruited from an allergy clinic in Eugene, OR. Participants were interviewed about symptoms and asthma history before enrollment to ensure that participants met eligibility requirements. Eligible participants were given the Asthma Control Test [35]. All participants gave informed consent. The ethics board of Oregon State University approved the study (protocol #8058).

Participants received an Android cell phone pre-loaded with the ELF Tracker application, passive chemical wristband sampling devices [36], and a mobile spirometer [37]. Participants were enrolled for a total of 14 days; 7 consecutive days during the summer and 7 consecutive days during the winter. Of the 35 participants, 6 participated for 7 days while the other 29 completed 14 days. Participants were enrolled in three different time periods consisting of 89 days in total: Summer 2017 (September 29-November 3); Winter 2018 (February 6-April 10); and Summer 2018 (September 7-October 12).

Twice a day (morning and evening) participants self-recorded three FEV$_1$ measurements using the Spirotel spirometer (Medical International Research, eHealth minilab, v1) and answered a short questionnaire about their protocol compliance, asthma medication use, and symptoms ([S1 File](#)). The participants carried the ELF phone, which cataloged and transmitted location (GPS) and spirometry data to the research team in real-time.[34] When enrolled, the participant completed a health questionnaire and was given the ELF toolkit to start the study the following morning. For this study, only data from the ELF phone, the questionnaire and spirometry data were utilized. Results from the silicone wristbands are not presented.

**Spirometry calibration, training, and processing**

American Thoracic Society (ATS) certified personnel conducted all training and spirometry calibration. All spirometers underwent calibration with a 3L syringe before distribution. All calibration tests were within +/- 0.15 L (5%) [38]. Each participant measured their FEV$_1$ in triplicate, on consecutive days, once in the morning and once in the evening. Participants were provided verbal instructions in the use of the spirometer and coached until a valid reading was obtained during enrollment. The ELF toolkit included a User Guide for each participant, along with a one-page abbreviated sheet of instructions for taking valid readings. These
readings were transmitted from the spirometer to the ELF phone and stored in a cloud. For both morning and evening measures, a valid FEV₁ reading was defined as the two highest FEV₁ measures at one-time point that were also within +/- 0.15 L of one another [39]. Valid readings were used as described below in the analyses and linked to exposure measures by the date and time of the reading.

**Self-reported symptoms and asthma medication usage**

Following each spirometry measurement, participants completed a brief survey documenting asthma medication and rescue bronchodilator use, and asthma symptoms (wheezing, coughing, shortness of breath, chest tightness or pain) within the last 6 hours. All participants were instructed to continue daily asthma medication and use their emergency bronchodilator medication as typically self-administered throughout the study.

**Location data**

Valid, time-stamped questionnaire and lung function data were used to identify the start and end dates/times for each participant within their study period. Missing GPS data were estimated by reviewing location coordinates immediately before and after the missing data. If these were the same latitude and longitude, the missing location data were estimated to be the same. If the data before and after the missing data contained different latitudes and longitudes, the timestamp, latitude, and longitude on either side of the gap were used to extrapolate the missing data using linear interpolation. The estimated data were visually checked for spatiotemporal errors.

**Exposure metrics**

**Air quality.** Hourly PM$_{2.5}$ data (parameter code 88502) from land-based air pollution monitors were downloaded from the Environmental Protection Agency (EPA) air quality index data [40] for Oregon for the years 2017 and 2018 (downloaded 03/18/2020). The GPS and EPA hourly data were rounded to the nearest hour and linked by date, time, and nearest location. The distance between each GPS point and air pollution monitor location was calculated. GPS data that were more than 50 kilometers away from a monitor were assigned as missing for PM$_{2.5}$ exposure. This was done to remove potential outliers while ensuring the homes of the participants were assigned exposures. The number of hours spent at each GPS location was multiplied by the PM$_{2.5}$ measurements to generate hourly time-weighted average exposure values. For analysis, the PM$_{2.5}$ exposure at the time of the lung function reading is indicated as 0 hour. The hourly time-weighted exposures were averaged to estimate exposure windows for 0–6, 0–12, 0–24, and 0–48 hours prior to the FEV₁ reading. Although the EPA provides ozone and nitrogen dioxide (NO2) data, not all monitoring locations measure these. In Oregon, most of the monitors that measure these air pollutants were located near Portland, OR which is over 150 km from Eugene, OR where the participants live.

**Temperature.** National Oceanic and Atmospheric Administration (NOAA) hourly local climatological data [41] for dry bulb globe temperature (DBGT) were downloaded for Oregon for 2017 and 2018 (downloaded 03/20/2020). The same aforementioned interpolation methodology applied for the location was used to generate missing hourly DBGT hourly measurements. The GPS data and DBGT hourly data were rounded to the nearest hour and linked by date, time, and nearest location. GPS data more than 50 kilometers away from a monitor were assigned as missing for DBGT exposure. The exposures were averaged to create hourly average DBGT exposure. For analysis, the exposure at the time of the lung function reading is indicated as 0 hour. The hourly DBGT was averaged to estimate exposure windows for 0–6, 0–12, 0–24, and 0–48 hours prior to the FEV₁ recording.
Statistical analysis

To evaluate how rescue bronchodilator use and measures of FEV\textsubscript{1} were associated with acute exposures to PM\textsubscript{2.5} and DBGT, each exposure (0 hour, 0–6, 0–12, 0–24, 0–48 hours prior to reading) was independently run in unadjusted and adjusted mixed-effect models. The participant was included in the model as a random effect to account for the potential dependence of their measurements PM\textsubscript{2.5} and DBGT exposures were also placed in the same adjusted model and checked for significant interactions. R (Version 3.5.0) was used for all data management and statistical analyses using linear and logistic mixed-effects models to account for within-subject variability in the outcome variables. P-values less than 0.05 were considered statistically significant.

Adjusted mixed-effects models were run with a priori chosen list of covariates based on findings from other panel studies that examined PM\textsubscript{2.5} or DBGT exposures and lung function [16,17,19–21,23,24,42–45]. Covariates included were age (linear and quadratic), morning or evening reading (morning/evening), normal daily asthma medication usage (yes/no), and time period (Summer 2017/Winter 2018/Summer 2018).

Rescue bronchodilator use. To evaluate if PM\textsubscript{2.5} was associated with rescue bronchodilator use the effects of PM\textsubscript{2.5} and DBGT were evaluated in separate mixed-effects logistic regression models with the participant included as a random effect. Neither splines nor interquartile ranges (IQR) PM\textsubscript{2.5} exposure transformations were found to significantly improve model fit. The 0 hour and cumulative PM\textsubscript{2.5} exposures were each placed in models with DBGT exposures to determine whether exposure to PM\textsubscript{2.5} changed while controlling for DBGT. Cross product terms were placed in the models to determine if any significant interaction with the air quality and temperature occurred that impacted bronchodilator use. Multicollinearity between DBGT and PM\textsubscript{2.5} exposure metrics was checked using the variance inflation factor.

Lung function (FEV\textsubscript{1}). Readings when rescue bronchodilator medication was self-administered within 6 hours of the reading were excluded from the analyses for FEV\textsubscript{1} to minimize residual pharmacological effects on the FEV\textsubscript{1} measures. To evaluate the impact of acute exposures on FEV\textsubscript{1}, the same variables and approach used in the logistic models (described above) were assessed in mixed-effects linear regression models. Similar to previous panel studies of lung function, FEV\textsubscript{1} was not transformed [16,17,19–21,23,24,26,28]. Adjusted models were then run with covariates selected a priori. Models were not significantly improved with splines nor IQR exposures for PM\textsubscript{2.5} and DBGT. Cross product terms were then placed in the models to determine if any significant interaction occurred. Multicollinearity between DBGT and PM\textsubscript{2.5} exposure metrics was checked using the variance inflation factor.

Sensitivity analyses. Multiple sensitivity analyses were conducted to evaluate various assumptions used in the mixed-effects regression models. The cut-off distance between EPA air monitors and GPS coordinates was changed to 25 kilometers instead of 50. Hourly time-weighted averages were generated for all PM\textsubscript{2.5} exposures using this new cut-off distance. The results from all the models, both linear and logistic, were compared to see how the models handled the larger number of missing values and the corresponding coefficients. The participant variable was run as a fixed-effect, instead of a random-effect, in all models to examine individual level changes in FEV\textsubscript{1}. Finally, a stratified analyses by summer and winter time periods were examined to determine how the PM\textsubscript{2.5} and DBGT effects differ by season.

Results

Participant and lung function readings

The average age of the participants was 49 years old (range: 21–74 years; SD = 15.5). There were 28 women and 7 men in the study. The majority of participants were Caucasian (85%).
Additional details about the study population can be found in Table 1. There were 23 participants enrolled in Summer 2017, 32 in Winter 2018, and 9 in Summer 2018. A total of 968 ELF measurements (spirometry and asthma symptom question responses) were collected (Table 2) and 625 (64.6%) were used for the analysis of FEV1, after excluding readings that were missing FEV1 values, used rescue bronchodilator medication, or were missing questionnaire data. For the rescue bronchodilator use analysis, 846 (87.4%) readings were used, following the exclusion of readings without questionnaire data.

Table 1. ELF participant demographic information.

| Variable                        | Count (% or Standard Deviation) |
|---------------------------------|---------------------------------|
| **Sex: N (%)**                  |                                 |
| Female                          | 28 (81%)                        |
| Male                            | 7 (19%)                         |
| **Age [years]: mean (SD), (Range)** | 49 (15.5 SD), 21–74            |
| **Height [inches]: mean (SD)**  | 66 (3.4 SD)                     |
| **Race: n (%)**                 |                                 |
| White                           | 30 (85%)                        |
| Black / African American        | 1 (3%)                          |
| American Indian/Alaska Native   | 1 (3%)                          |
| More than One Race              | 1 (3%)                          |
| Unknown/Other                   | 2 (6%)                          |
| **Ethnicity: n (%)**            |                                 |
| Hispanic or Latino              | 3 (8%)                          |
| Not Hispanic or Latino          | 26 (75%)                        |
| Decline to answer               | 6 (17%)                         |
| **Years with asthma: mean (SD), (Range)** | 35.4 (19.0), 1–72            |
| **Asthma Control Test: mean (SD), (Range)** | 20.9 (3.0), 13–25          |

Table 2. Lung function and exposure metrics by time period.

| Time Period | Summer 2017 | Winter 2018 | Summer 2018 |
|-------------|-------------|-------------|-------------|
| **Number of Participants** | 23          | 32          | 9           |
| **ELF Measurements** |             |             |             |
| Total Measurements Recorded | 341         | 490         | 137         |
| Missing Questionnaire | 27 (7.9%)  | 65 (13.3%)  | 20 (14.6%) |
| Rescue Bronchodilator Used | 28 (8.2%)  | 34 (6.9%)   | 6 (4.4%)   |
| Missing FEV1 Reading | 61 (17.9%)  | 78 (15.9%)  | 24 (17.5%) |
| Valid Measure* | 225 (65.9%) | 313 (63.9%) | 87 (63.5%) |
| **FEV1 Measures** |             |             |             |
| Mean (ml) | 2,389       | 2,468       | 2,509       |
| Interquartile Range (ml) | 1,870–2,820 | 2,025–2,885 | 2,150–2,780 |
| **Number of GPS points** |             |             |             |
| 28,727     | 31,731      | 9,170       |
| **Average Minutes Between GPS points** | 9.45 mins | 12.2 mins | 12.2 mins |
| **Average Distance from Air Pollution Monitors (Kilometers)** | 12.7 KM | 8.94 KM | 10.7 KM |
| **Average Monitor PM2.5 (μg/m³)** | 29.0 μg/m³ | 4.33 μg/m³ | 9.56 μg/m³ |
| **Average Distance from Temperature Monitors (Kilometers)** | 18.5 KM | 14.8 KM | 17.4 KM |
| **Average Dry Bulb Globe Temperature (°F)** | 66.7°F | 43.2°F | 72.3°F |

* No rescue bronchodilator, no missing questionnaire, and valid FEV1 reading. Used in linear regression models.
**Spatiotemporal exposure metrics for PM$_{2.5}$ and DBGT**

Of the 66,708 GPS points collected, 323 (0.5%) and 1,198 (1.8%) were over 50 km from the nearest stationary air pollution and DBGT monitor. Details about the interpolation of GPS data can be found in [S1 File](#). Of the 968 total readings for FEV$_1$ for all participants, only 2 (0.2%) readings were missing PM$_{2.5}$ exposures and only 10 (1.0%) were missing DBGT exposure estimates. Of these, only 2 (0.2%) readings were missing both PM$_{2.5}$ and DBGT exposure estimates. Details of these metrics can be found in [Table 2](#).

**Impacts of PM$_{2.5}$ and DBGT on rescue bronchodilator use**

There were no significant associations between DBGT and rescue bronchodilator use in adjusted logistic regression models. Cumulative PM$_{2.5}$ exposures of 0–12, 0–24, and 0–48 hours prior to readings were significantly associated with rescue bronchodilator use. The strongest association between cumulative PM$_{2.5}$ and bronchodilator medication use was identified at the 0–24 (OR = 1.030; 95% CI = 1.013–1.048; p-value < 0.001) and 0–48 (OR = 1.036; 95% CI = 1.016–1.056; p-value < 0.001) hours prior to spirometer use. Results from exposures in unadjusted and adjusted logistic models can be found in [S1 File](#) for PM$_{2.5}$ and DBGT.

When temperature was taken into account with PM$_{2.5}$, the strongest association between cumulative PM$_{2.5}$ exposures and the use of rescue bronchodilator was identified at the 0–24 (OR = 1.030; 95% CI = 1.012–1.049; p-value = 0.001) and 0–48 hours (OR = 1.030; 95% CI = 1.013–1.057; p-value = 0.001) prior to spirometer use (Table 3). With PM$_{2.5}$ and DBGT each in the model, no significant associations between DBGT and rescue bronchodilator use remained. All 25 combinations of DBGT and PM$_{2.5}$ exposure durations were tested for interactions (multiplicative or additive) but none were statistically significant.

**Impacts of PM$_{2.5}$ and DBGT on FEV$_1$**

In the adjusted models for PM$_{2.5}$ and FEV$_1$, there was only one significant association for 0–12 hours (b = 0.835; SE = 0.411; p-value = 0.042). In the adjusted models for DBGT and FEV$_1$, all exposure windows (Hour 0, 0–6, 0–24, 0–48) except 0–12 were found to have significant associations with FEV$_1$. DBGT hour 0 (p-value < 0.001) and 0–6 (p-value < 0.001) had the biggest impact on FEV$_1$. The results from exposures in unadjusted and adjusted linear regression models can be found in [S1 File](#) for PM$_{2.5}$ and DBGT.

---

**Table 3. Adjusted odds ratios of rescue bronchodilator use for PM$_{2.5}$ (1 $\mu$g/m$^3$) and temperature (1˚F) in the same model.**

| Time  | PM$_{2.5}$ (1 $\mu$g/m$^3$) | **OR** | **95% CI** | **p-value** | Dry Bulb Globe Temperature (1˚F) | **OR** | **95% CI** | **p-value** |
|-------|-----------------------------|-------|-------------|-------------|---------------------------------|-------|-------------|-------------|
| 0     |                             | 1.016 | 0.988–1.046 | 0.261       | 1.017                          | 0.975–1.061 | 0.438       |
| 0–6   |                             | 1.012 | 0.999–1.026 | 0.071       | 1.017                          | 0.967–1.055 | 0.652       |
| 0–12  |                             | 1.021 | 1.005–1.036 | **0.007**   | 0.987                          | 0.941–1.035 | 0.582       |
| 0–24  |                             | 1.030 | 1.012–1.049 | **0.001**   | 1.009                          | 0.945–1.077 | 0.794       |
| 0–48  |                             | 1.035 | 1.013–1.057 | **0.001**   | 1.018                          | 0.945–1.097 | 0.635       |

Logistic model
Rescue_Meds=PM$_{2.5}$+DBGT+Medication+MornOrEven+TimePeriod+age+age$^2$+(1|Participant_ID).
Rescue_Meds = 1 (used rescue bronchodilator within 6 hours of reading) or 0 (didn’t use within 6 hours).
MornOrEven = Morning (04:00–12:59) or Evening readings (13:00–1:00).
Medication = 1 (used non-rescue asthma medication) or 0 (didn’t use).
TimePeriod = Summer 2017, Winter 2018, or Summer 2018.

[https://doi.org/10.1371/journal.pone.0270412.t003](https://doi.org/10.1371/journal.pone.0270412.t003)
Table 4. Adjusted change in respiratory function per increase in PM$_{2.5}$ (1-$\mu$g/m$^3$) and temperature (1˚F) in the same model.

| Time  | PM$_{2.5}$ (1 $\mu$g/m$^3$) |  |  | Dry Bulb Globe Temperature (1˚F) |  |  |
|-------|-----------------------------|---|---|---------------------------------|---|---|
|       | $\beta$ | SE ($\beta$) | p-value | $\beta$ | SE ($\beta$) | p-value |
| 0     | 0.745 | 0.627 | 0.234 | 3.527 | 0.879 | <0.001 |
| 0–6   | 0.750 | 0.366 | 0.076 | 2.885 | 0.903 | 0.001 |
| 0–12  | 0.757 | 0.418 | 0.070 | 1.212 | 1.005 | 0.228 |
| 0–24  | 0.449 | 0.490 | 0.359 | 2.418 | 1.272 | 0.057 |
| 0–48  | 0.223 | 0.586 | 0.704 | 2.991 | 1.446 | 0.038 |

Adjusted linear model
fev1_ml~PM$_{2.5}$+DBGT+Medication+MornOrEven+TimePeriod+age+age^2+(1|Participant_ID).
MornOrEven = Morning (04:00–12:59) or Evening readings (13:00–1:00).
Medication = 1 (used non-rescue asthma medication) or 0 (didn’t use).
TimePeriod = Summer 2017, Winter 2018, or Summer 2018.

https://doi.org/10.1371/journal.pone.0270412.t004

When PM$_{2.5}$ and DBGT were each in the model, both hour 0 and hours 0–6 for DBGT remained highly significant (p-value < 0.001), while all PM$_{2.5}$ exposures were not significant (Table 4). All adjusted models reported increases in FEV$_1$ as PM$_{2.5}$ levels increased regardless of whether DBGT was taken into account or not (S1 File). No cross-product interactions between DBGT and PM$_{2.5}$ were significant. All the cross-product terms were shown that as PM$_{2.5}$ and DBGT increased, FEV$_1$ increased.

Sensitivity and stratified analyses
Results from the sensitivity and stratified analyses can be found in the S1 File. When GPS points over 25 km away from an air pollution monitor were removed from calculations for hourly time-weighted average exposure to PM$_{2.5}$, the results remained relatively similar to the original findings. DBGT was only significant for Hour 0 and 0–6 hours before a reading while PM$_{2.5}$ was only significant for 0–6 and 0–12 hours before a reading. Regardless of the season, when PM$_{2.5}$ or DBGT increased, FEV$_1$ increased. For rescue bronchodilator use, PM$_{2.5}$ was the only exposure to be significantly associated with increased use. Using the participant as a fixed-effect did not significantly change the findings from the linear and logistic regression.

Stratified analyses revealed no significant associations between PM$_{2.5}$, DBGT, and FEV$_1$ during the winter (S1 File). DBGT was significantly associated with FEV$_1$ during the summer (S1 File). For rescue bronchodilator use, PM$_{2.5}$ exposure was significantly associated with increased use during the summer but not during the winter (Table 5). For the winter, only PM$_{2.5}$ 0–6 hours before a reading was found to have a significant association with rescue bronchodilator use. All of the PM$_{2.5}$ exposures during the winter were found to decrease the likelihood that participants used rescue bronchodilator medication as PM$_{2.5}$ levels increased (Table 6).

Discussion
Health effects of PM$_{2.5}$ and DBGT exposure
This study found that as PM$_{2.5}$ concentrations increased so did FEV$_1$ measurements, independent of the model used. This is similar to findings from other air pollution panel studies that did not analyze lung function readings when rescue bronchodilator medication was used, or that analyzed those readings separately [27,30,46]. This association may partially be explained by the exclusion of FEV$_1$ readings with rescue bronchodilator use. We did find that the average
exposure to PM$_{2.5}$ was higher when participants reported the use of their rescue bronchodilators. Since we excluded FEV$_1$ readings measured within 6 hours of rescue bronchodilator use to minimize confounding by residual drug-induced bronchodilation, this removed some of the higher PM$_{2.5}$ readings from the linear regression analysis looking at the association of PM$_{2.5}$ and FEV$_1$.

Comparisons to other panel studies

Previous panel studies of repeated lung function measures and exposure to ambient PM$_{2.5}$ have reported conflicting results, with several reporting no association [16,17,19,20], and others reporting negative associations [18,22–24,30]. Wu et al. reported that estimated PM$_{2.5}$ effects were generally stronger in the presence of high temperatures than in low temperatures. [22] Although Wu et al. suggested that ambient air pollution and temperature may interact synergistically to adversely lower FEV$_1$, our study did not find any interactions. As we mentioned above, the removal of lung function readings taken within 6 hours of rescue bronchodilator use may have obscured the impact of PM$_{2.5}$ on FEV$_1$ and any possible interactions.

This study illustrated that the use of a rescue bronchodilator is associated with acute previous cumulative exposure to ambient PM$_{2.5}$ but not elevated temperatures. Therefore, evaluating impacts of PM$_{2.5}$ using FEV$_1$ in asthmatics is problematic, as to self-manage their health

Table 5. Adjusted odds ratios of rescue bronchodilator usage for PM$_{2.5}$ and DBGT in the same model for participants in the summer.

| Time | PM$_{2.5}$ (1 μg/m$^3$) | Dry Bulb Globe Temperature (1˚F) |
|------|------------------------|---------------------------------|
|      | OR | 95% CI | p-value | OR | 95% CI | p-value |
| 0    | 1.032 | 0.997–1.068 | 0.076 | 1.013 | 0.946–1.084 | 0.712 |
| 0–6  | 1.018 | 1.001–1.035 | 0.033 | 0.981 | 0.912–1.056 | 0.615 |
| 0–12 | 1.027 | 1.008–1.046 | 0.006 | 0.946 | 0.874–1.024 | 0.173 |
| 0–24 | 1.033 | 1.010–1.056 | 0.001 | 0.990 | 0.883–1.110 | 0.860 |
| 0–48 | 1.041 | 1.014–1.069 | 0.003 | 0.991 | 0.872–1.125 | 0.885 |

Logistic model

Rescue_Meds$\sim$PM$_{2.5}+DBGT+Medication+MornOrEven$+age+age^2$$+$(1$|Participant_ID$).

Rescue_Meds = 1 (used rescue bronchodilator within 6 hours of reading) or 0 (didn’t use within 6 hours) MornOrEven = Morning (04:00–12:59) or Evening readings (13:00–1:00).

Medication = 1 (used non-rescue asthma medication) or 0 (didn’t use).

https://doi.org/10.1371/journal.pone.0270412.t005

Table 6. Adjusted odds ratios of rescue bronchodilator usage for PM$_{2.5}$ and DBGT in the same model for participants in the winter.

| Time | PM$_{2.5}$ (1 μg/m$^3$) | Dry Bulb Globe Temperature (1˚F) |
|------|------------------------|---------------------------------|
|      | OR | 95% CI | p-value | OR | 95% CI | p-value |
| 0    | 0.724 | 0.478–1.096 | 0.127 | 0.994 | 0.928–1.066 | 0.870 |
| 0–6  | 0.502 | 0.288–0.875 | 0.015 | 0.970 | 0.901–1.045 | 0.422 |
| 0–12 | 0.734 | 0.490–1.100 | 0.134 | 0.961 | 0.889–1.038 | 0.308 |
| 0–24 | 0.854 | 0.581–1.256 | 0.423 | 0.997 | 0.912–1.090 | 0.943 |
| 0–48 | 0.881 | 0.563–1.379 | 0.579 | 1.013 | 0.912–1.124 | 0.816 |

Logistic model

Rescue_Meds$\sim$PM$_{2.5}+DBGT+Medication+MornOrEven$+age+age^2$$+$(1$|Participant_ID$).

Rescue_Meds = 1 (used rescue bronchodilator within 6 hours of reading) or 0 (didn’t use within 6 hours).

MornOrEven = Morning (04:00–12:59) or Evening readings (13:00–1:00).

Medication = 1 (used non-rescue asthma medication) or 0 (didn’t use).

https://doi.org/10.1371/journal.pone.0270412.t006
they may require rescue bronchodilator use obscuring any effect that PM$_{2.5}$ may have on FEV$_1$ measures. Studies in healthy adults, who may be less susceptible, may further elucidate impacts on FEV$_1$ from acute exposures to PM$_{2.5}$, although such an approach may be less sensitive as healthy adults may have a more stable FEV$_1$. The PM$_{2.5}$ exposure latencies from this study showed that the PM$_{2.5}$ concentrations at the time a spirometer reading was taken was never significantly associated with rescue bronchodilator use. Our study adds to the growing body of literature on the impact of latent air pollution exposures on asthmatics. Our stratified analyses by summer and winter showed that the impact of PM$_{2.5}$ was different depending on the season. During the summer, increased PM$_{2.5}$ cumulative exposures were all significantly associated with an increased risk of rescue bronchodilator use. All of the ORs for PM$_{2.5}$ during the winter were below 1 which showed that participants were less likely to use rescue bronchodilators as PM$_{2.5}$ levels increased.

**Application of findings**

Our findings suggest that cumulative, ambient air pollution levels impact rescue bronchodilator use in asthmatics most during summer time. As climate change continues to worsen air quality (duration and concentration) in this region, as has been seen in the summer of 2020 [47], public health and medical management of the health impacts for vulnerable populations is critical.

**Potential limitations of the study**

We acknowledge several limitations of the study. The participants were a convenience sample recruited at an asthma clinic. The applicability of the results in this study could be limited due to several factors. We acknowledge that the small sample size ($n = 35$) could have limited our ability to detect significant changes in FEV$_1$. Additionally, our study was comprised mostly of females (81%) and white (85%) which limits the generalizability of the findings to the overall adult asthmatic population. The exposure metrics used in the study were dependent on participant compliance (i.e. carrying the phone with them), but every individual who participated twice in our study recorded 84 lung function tests which we feel is an acceptable number of tests to evaluate changes over time and their validity. Overall compliance was high, as the average percentage of interpolated data by hour was less than 8% ([S1 Table in S1 File](#)).

The exposure metrics generated for this study represent ambient PM$_{2.5}$ and temperature levels that may not reflect the actual exposures for individuals with time spent inside. We decided to use publicly available sources of exposure data from the EPA that were used in our previous study [34] but the distribution of GPS location data varied considerably from this study. Our sensitivity analyses also showed that reducing the cut-off point between monitors and participant GPS locations by half did not significantly change the results. The decision to adjust all models by age, time of reading, time period, and participant identification number were made *a priori*. Participants continued to use asthma medication throughout the study and rescue bronchodilator medication was self-reported for approximately 5% of FEV$_1$ readings taken.

There are several strengths of the study. They include: (1) repeated observations for participants across different seasons and different times of day; (2) wide distribution of air quality levels due to wildfire smoke in the summer of 2017; (3) study with asthmatics and; (4) community engaged research that highlights illustrates how participants can correctly and accurately collect their own data.

**Conclusion**

As climate change continues to increase temperatures and consequently air pollution levels, it is important to study how environmental conditions impact susceptible populations. This
study investigates how environmental factors can impact human health using community gathers data. Our research identifies a caveat in measuring lung function in asthmatics since the exposure causes respiratory distress. More research is needed to conclusively determine the short-term health effects of air pollution and/or temperature to better understand the cumulative impact these exposures can have on the health of vulnerable communities.

Supporting information

S1 Data. (XLSX)
S1 File. (DOCX)

Acknowledgments

We gratefully acknowledge the Oregon Allergy Associates (Eugene, OR) as well as all study participants for their time.

Author Contributions

Conceptualization: Laurel Kincl, Diana Rohlman, Rachel L. Miller, Katrina M. Waters, Julie B. Herbstman, Kim A. Anderson.
Data curation: Richard Evoy, Laurel Kincl, Diana Rohlman, Lisa M. Bramer, Holly M. Dixon, Michael Barton, Aaron Phillips.
Formal analysis: Richard Evoy, Diana Rohlman, Lisa M. Bramer.
Funding acquisition: Laurel Kincl, Katrina M. Waters, Julie B. Herbstman, Kim A. Anderson.
Methodology: Richard Evoy, Laurel Kincl, Diana Rohlman, Perry Hystad, Harold Bae.
Software: Michael Barton, Aaron Phillips.
Supervision: Laurel Kincl, Rachel L. Miller, Katrina M. Waters, Julie B. Herbstman, Kim A. Anderson.
Writing – original draft: Richard Evoy, Laurel Kincl, Diana Rohlman.
Writing – review & editing: Richard Evoy, Laurel Kincl, Diana Rohlman, Lisa M. Bramer, Holly M. Dixon, Perry Hystad, Harold Bae, Michael Barton, Aaron Phillips, Rachel L. Miller, Katrina M. Waters, Julie B. Herbstman, Kim A. Anderson.

References

1. Brunekreef B, Holgate ST. Air pollution and health. The Lancet. 2002; 360: 1233–1242. https://doi.org/10.1016/S0140-6736(02)11274-8
2. Balbus J, Crimmins A, Gamble JL, Easterling DR, Kunkel KE, Saha S, et al. Ch. 1: Introduction: Climate Change and Human Health. The Impacts of Climate Change on Human Health in the United States: A Scientific Assessment. U.S. Global Change Research Program; 2016. https://doi.org/10.7930/J0VX0DFW
3. Hyrkäs H, Ikäheimo TM, Jaakkola JJK, Jaakkola MS. Asthma control and cold weather-related respiratory symptoms. Respir Med. 2016; 113: 1–7. https://doi.org/10.1016/j.rmed.2016.02.005 PMID: 27021573
4. D’Amato M, Molino A, Calabrese G, Cecchi L, Annesi-Maesano I, D’Amato G. The impact of cold on the respiratory tract and its consequences to respiratory health. Clin Transl Allergy. 2018; 8: 20. https://doi.org/10.1186/s13601-018-0208-9 PMID: 29997887
5. Li S, Baker PJ, Jalaludin BB, Marks GB, Denison LS, Williams GM. Ambient temperature and lung function in children with asthma in Australia. Eur Respir J. 2014; 43: 1059–1066. https://doi.org/10.1183/09031936.00079313 PMID: 24311765

6. Collaco JM, Appel LJ, McGreedy J, Cutting GR. The relationship of lung function with ambient temperature. PLOS ONE. 2018; 13: e0191409. https://doi.org/10.1371/journal.pone.0191409 PMID: 29346418

7. Mott JA, Mannino DM, Alverson CJ, Kiyu A, Hashim J, Lee T, et al. Cardiorespiratory hospitalizations associated with smoke exposure during the 1997 Southeast Asian forest fires. Int J Hyg Environ Health. 2005; 208: 75–85. https://doi.org/10.1016/j.ijheh.2005.01.018 PMID: 15881981

8. Alman BL, Pfister G, Hao H, Stowell J, Hu X, Liu Y, et al. The association of wildfire smoke with respiratory and cardiovascular emergency department visits in Colorado in 2012: a case crossover study. Environ Health. 2016; 15: 64. https://doi.org/10.1186/s12940-016-0146-8 PMID: 27259511

9. Dohrenwend PB, Le MV, Bush JA, Thomas CF. The Impact on Emergency Department Visits for Respiratory Illness During the Southern California Wildfires. West J Emerg Med. 2013; 14: 79–84. https://doi.org/10.5811/westjem.2012.10.6917 PMID: 23599837

10. Wettstein Zachary S., Hoshiko Sumi, Fahimi Jahan, Harrison Robert J., Cascio Wayne E., Rappold 11. Nurmagambetov T, Kuwahara R, Garbe P. The Economic Burden of Asthma in the United States, McClure CD, Jaffe DA. US particulate matter air quality improves except in wildfire-prone areas. Proc Paulin L, Hansel N. Particulate air pollution and impaired lung function. F1000Research. 2016; 5. Abelsohn A, Stieb DM. Health effects of outdoor air pollution. Can Fam Physician. 2011; 57: 881–887.

11. Lagorio S, Forastiere F, Pistelli R, Iavarone I, Michelozzi P, Fano V, et al. Air pollution and lung function among susceptible adult subjects: a panel study. Environ Health. 2006; 5: 11. https://doi.org/10.1186/1476-059X-5-11 PMID: 16674831

12. McIntyre CD, Jaffe DA. US particulate matter air quality improves except in wildfire-prone areas. Proc Natl Acad Sci. 2018; 115: 7901–7906. https://doi.org/10.1073/pnas.1804353115 PMID: 30012611

13. Abelsohn A, Steb DM. Health effects of outdoor air pollution. Can Fam Physician. 2011; 57: 881–887. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155438/. PMID: 21841106

14. Paulin L, Hansel N. Particulate air pollution and impaired lung function. F1000Research. 2016; 5. https://doi.org/10.12688/f1000research.7108.1 PMID: 26962445

15. Weinmayr G, Romeo E, De Sario M, Weiland SK, Forastiere F. Short-Term Effects of PM10 and NO2 on Respiratory Health among Children with Asthma or Asthma-like Symptoms: A Systematic Review and Meta-Analysis. Environ Health Perspect. 2009; 118: 449–457. https://doi.org/10.1289/ehp. 0900844 PMID: 20064785

16. Lagorio S, Forastiere F, Pistelli R, lavarone I, Michelozzi P, Fano V, et al. Air pollution and lung function among susceptible adult subjects: a panel study. Environ Health. 2006; 5: 11. https://doi.org/10.1186/1476-059X-5-11 PMID: 16674831

17. Silkoff PE, Zhang L, Dutton S, Langmack EL, Vedal S, Murphy J, et al. Winter air pollution and disease parameters in advanced chronic obstructive pulmonary disease panels residing in Denver, Colorado. J Allergy Clin Immunol. 2005; 115: 337–344. https://doi.org/10.1016/j.jaci.2004.11.035 PMID: 15696092

18. Ni Y, Wu S, Ji W, Chen Y, Zhao B, Shi S, et al. The exposure metric choices have significant impact on the association between short-term exposure to outdoor particulate matter and changes in lung function: Findings from a panel study in chronic obstructive pulmonary disease patients. Sci Total Environ. 2016; 542: 264–270. https://doi.org/10.1016/j.scitotenv.2015.10.114 PMID: 26519586

19. Peacock JL, Anderson HR, Bremner SA, Marston L, Seemungal TA, Strachan DP, et al. Outdoor air pollution and respiratory health in patients with COPD. Thorax. 2011; 66: 591–596. https://doi.org/10.1136/thx.2010.155358 PMID: 21459856

20. Hartog JJ de, Ayres JG, Karakatsani A, Anathitis A, Brink H ten, Hamerl K, et al. Lung function and indicators of exposure to indoor and outdoor particulate matter among asthma and COPD patients. Occup Environ Med. 2010; 67: 2–10. https://doi.org/10.1136/oem.2008.040857 PMID: 19736175

21. Lin Z, Gu Y, Liu C, Song Y, Bai C, Chen R, et al. Effects of ambient temperature on lung function in patients with chronic obstructive pulmonary disease: A time-series panel study. Sci Total Environ. 2018; 619–620: 360–365. https://doi.org/10.1016/j.scitotenv.2017.11.035 PMID: 29156256

22. Wu S, Deng F, Hao Y, Wang X, Zheng C, Lv H, et al. Fine particulate matter, temperature, and lung function in healthy adults: Findings from the HVNR study. Chemosphere. 2014; 108: 168–174. https://doi.org/10.1016/j.chemosphere.2014.01.032 PMID: 24548647

23. Dales R, Chen L, Frescura AM, Liu L, Villeneuve PJ. Acute effects of outdoor air pollution on forced expiratory volume in 1 s: a panel study of schoolchildren with asthma. Eur Respir J. 2009; 34: 316–323. https://doi.org/10.1183/09031936.00138908 PMID: 19251781

24. Jacobson L da SV, Hac0n DJ de, Ignotti E, Artaxo P, Ponce de Leon ACM. Association between fine particulate matter and the peak expiratory flow of schoolchildren in the Brazilian...
subequatorial Amazon: a panel study. Environ Res. 2012; 117: 27–35. https://doi.org/10.1016/j.envres.2012.05.006 PMID: 22683314

25. Escamilla-Nuñez M-C, Barraza-Villatorreal A, Hernandez-Cadena L, Moreno-Macias H, Ramirez-Aguilar M, Sienra-Monge J-J, et al. Traffic-related air pollution and respiratory symptoms among asthmatic children, resident in Mexico City: the EVA cohort study. Respir Res. 2008; 9: 74. https://doi.org/10.1186/1465-9921-9-74 PMID: 19014608

26. Trenga CA, Sullivan JH, Schildcrout JS, Shepherd KP, Shapiro GG, Liu L-JS, et al. Effect of particulate air pollution on lung function in adult and pediatric subjects in a Seattle panel study *. Chest. Jun 2006129: 1614–. Available: http://link.gale.com/apps/docs/A147745811/HRCA?u=s84052484&sid=zotero&xid=3e182b74. Accessed 31 May 2020.

27. Delfino Ralph J., Staimer Norbert, Tjoa Thomas, Gillen Dan, Kleinman Michael T., Sioutas Constanti, et al. Personal and Ambient Air Pollution Exposures and Lung Function Decrements in Children with Asthma. Environ Health Perspect. 2008; 116: 550–558. https://doi.org/10.1289/ehp.10911 PMID: 18414642

28. Smargiassi A, Goldberg MS, Wheeler AJ, Plante C, Valois M-F, Mallach G, et al. Associations between personal exposure to air pollutants and lung function tests and cardiovascular indices among children with asthma living near an industrial complex and petroleum refineries. Environ Res. 2014; 132: 38–45. https://doi.org/10.1016/j.envres.2014.03.030 PMID: 24742726

29. Orellano P, Quaranta N, Reynoso J, Baib Bi, Vasquez J. Effect of outdoor air pollution on asthma exacerbations in children and adults: Systematic review and multilevel meta-analysis. PLOS ONE. 2017; 12: e0174050. https://doi.org/10.1371/journal.pone.0174050 PMID: 28319180

30. Jansen Karen L., Larson Timothy V., Koenig Jane Q., Mar Therese F., Fields Carrie, Stewart Jim, et al. Associations between Health Effects and Particulate Matter and Black Carbon in Subjects with Respiratory Disease. Environ Health Perspect. 2005; 113: 1741–1746. https://doi.org/10.1289/ehp.8153 PMID: 16330357

31. Saltenrich N. Between Extremes: Health Effects of Heat and Cold. Environ Health Perspect. 2015;123.

32. Barnum P. Impacts of Oregon’s 2017 Wildfire Season: Time for a crucial conversation. Oregon Forest Resources Institute; 2018 Jan. Available: https://oregonforests.org/sites/default/files/2018-01/OFRI%202017%20Wildfire%20Report%20-%20FINAL%2001-02-18.pdf.

33. Lepeule J, Litonjua AA, Gasparrini A, Koutrakis P, Sparrow D, Vokonas PS, et al. Lung function associations with outdoor temperature and relative humidity and its interaction with air pollution in the elderly. Environ Res. 2018; 165: 110–117. https://doi.org/10.1016/j.envres.2018.03.039 PMID: 29684737

34. Schatz M, Sorkness CA, Li-JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006; 117: 549–556. https://doi.org/10.1016/j.jaci.2006.01.011 PMID: 16522452

35. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019; 200: e70–e88. https://doi.org/10.1164/rccm.201908-1590ST PMID: 31613151

36. EPA. AirData website File Download page. In: Pre-Generated Data Files [Internet]. [cited 26 Aug 2020]. Available: https://aqs.epa.gov/aqsweb/airdata/download_files.html.

37. NOAA. Local Climatological Data (LCD) | Data Tools | Climate Data Online (CDO) | National Climatic Data Center (NCDC). In: Data Tools: Local Climatological Data (LCD) [Internet]. [cited 24 Aug 2020]. Available: https://www.ncdc.noaa.gov/cdo-web/datalos/lcd.

38. Li H, Bai H, Yang C, Chen R, Wang C, Zhao Z, et al. Acute effects of ambient temperature and particulate air pollution on fractional exhaled nitric oxide: A panel study among diabetic patients in Shanghai, China. J Epidemiol. 2017; 27: 584–589. https://doi.org/10.1016/j.jepidemi.2017.01.002 PMID: 28645522
43. Stergiopoulou A, Katavouta G, Samoli E, Dimakopoulou K, Papageorgiou I, Karagianni P, et al. Assessing the associations of daily respiratory symptoms and lung function in schoolchildren using an Air Quality Index for ozone: Results from the RESPOZE panel study in Athens, Greece. Sci Total Environ. 2018; 633: 492–499. https://doi.org/10.1016/j.scitotenv.2018.03.159 PMID: 29579660

44. Stieb DM, Shutt R, Kauri L, Mason S, Chen L, Szyszkowicz M, et al. Cardiorespiratory Effects of Air Pollution in a Panel Study of Outdoor Physical Activity and Health in Rural Older Adults. J Occup Environ Med. 2017; 59: 356–364. https://doi.org/10.1097/JOM.0000000000000954 PMID: 28628045

45. Stieb D, Shutt R, Kauri L, Roth G, Szyszkowicz M, Dobbin N, et al. Cardiorespiratory Effects of Air Pollution in a Panel Study of Winter Outdoor Physical Activity in Older Adults. J Occup Environ Med. 2018; 60: 673–682. https://doi.org/10.1097/JOM.0000000000001334 PMID: 29668530

46. Trenga CA, Sullivan JH, Schildcrout JS, Shepherd KP, Shapiro GG, Liu L-JS, et al. Effect of particulate air pollution on lung function in adult and pediatric subjects in a Seattle panel study. Chest. 2006; 129: 1614–1622. https://doi.org/10.1378/chest.129.6.1614 PMID: 16778283

47. Wildfire smoke brings record poor air quality to Oregon, new data shows. In: AIR, LAND & WATER [Internet]. 16 Sep 2020 [cited 28 Sep 2020]. Available: https://deqblog.com/2020/09/16/wildfire-smoke-brings-record-poor-air-quality-to-oregon-new-data-shows/